Screener
Beta Bionics BBNX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Beta Bionics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-323777
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Other long-term liabilities | 82 | 1,011 |
| Operating lease liability | (791) | (567) |
| Deferred revenue | 481 | 1,012 |
| Net cash used in operating activities | (38,454) | (33,569) |
| Cash flows from investing activities: | ||
| Purchases of short-term investments | — | (190,768) |
| Purchases of long-term investments | (44,812) | (31,069) |
| Proceeds from maturities and redemptions of short-term investments | 96,000 | 51,000 |
Item 1. Financial Statements.
FAQ
- What is Beta Bionics's operating cash flow?
- Beta Bionics (BBNX) reported operating cash flow of -$14.62M in Q2 2026.
- How has Beta Bionics's operating cash flow changed year-over-year?
- Beta Bionics's operating cash flow decreased by 7.6% year-over-year, from -$13.59M to -$14.62M.
- What is the long-term trend for Beta Bionics's operating cash flow?
- Over 2 years (2023 to 2025), Beta Bionics's operating cash flow has grown at a 25.3% compound annual growth rate (CAGR), from -$32.45M to -$50.93M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Beta Bionics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude